Linda Hagerman

583 total citations
16 papers, 347 citations indexed

About

Linda Hagerman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Linda Hagerman has authored 16 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Linda Hagerman's work include Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (4 papers). Linda Hagerman is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (4 papers). Linda Hagerman collaborates with scholars based in Canada, United States and United Kingdom. Linda Hagerman's co-authors include Elizabeth A. Eisenhauer, Lesley Seymour, Bingshu E. Chen, Kerry J. Savage, Susan Ellard, Karl Bélanger, Teresa M. Petrella, Suzanne Kamel‐Reid, Ralph Wong and Michael Smylie and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Linda Hagerman

15 papers receiving 341 citations

Peers

Countries citing papers authored by Linda Hagerman

Since Specialization

Citations

This map shows the geographic impact of Linda Hagerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Hagerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Hagerman more than expected).

Fields of papers citing papers by Linda Hagerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Hagerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Hagerman. The network helps show where Linda Hagerman may publish in the future.

Co-authorship network of co-authors of Linda Hagerman

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Hagerman. A scholar is included among the top collaborators of Linda Hagerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Hagerman. Linda Hagerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC) 2023 ·Cancer Research ·John Hilton, David W. Cescon, A. Robinson, Sukhbinder Dhesy‐Thind, Sara Taylor, Arif Awan, Terry L. Ng, Moira Rushton, (unknown), (unknown), (unknown), Linda Hagerman, (unknown), (unknown), Dongsheng Tu, Lesley Seymour, Pierre-Olivier Gaudreau	1
2	Abstract P3-07-10: CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC) 2023 ·Cancer Research ·Philippe L. Bédard, Mihaela Mates, John Hilton, Nathalie LeVasseur, Arif Awan, Amirrtha Srikanthan, David W. Cescon, Karen A. Gelmon, A. Robinson, (unknown), Irene Li, (unknown), (unknown), Linda Hagerman, (unknown), (unknown), Lesley Seymour, Moira Rushton, Pierre-Olivier Gaudreau	3
3	Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237 2023 ·Cancer Research ·David W. Cescon, John Hilton, Philippe L. Bédard, Phillip Blanchette, Rossanna C. Pezo, Ayesha Bashir, Vikaash Kumar, Terry L. Ng, Arif Awan, (unknown), (unknown), Linda Hagerman, (unknown), (unknown), Jesús Fuentes‐Antrás, Lesley Seymour, Dongsheng Tu, Pierre-Olivier Gaudreau, Moira Rushton	0
4	38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC) 2021 ·Annals of Oncology ·Mihaela Mates, Philippe L. Bédard, John Hilton, Karen A. Gelmon, Amirrtha Srikanthan, Arif Awan, (unknown), Caroline Lohrisch, A. Robinson, Dongsheng Tu, Linda Hagerman, (unknown), (unknown), (unknown), (unknown), Joshua Edwards, (unknown), Moira Rushton, (unknown)	2
5	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia 2020 ·Leukemia & lymphoma ·Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodríguez, (unknown), Lawrence Panasci, Bingshu E. Chen, Annette E. Hay	6
6	19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC) 2020 ·Annals of Oncology ·Philippe L. Bédard, Mihaela Mates, Karen A. Gelmon, John Hilton, Dongping Tu, (unknown), (unknown), (unknown), Joshua Edwards, David Warr, Caroline Lohrisch, (unknown), Amirrtha Srikanthan, A. Robinson, Linda Hagerman, Lesley Seymour, Moira Rushton, David W. Cescon	4
7	Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies 2020 ·Cancer Research ·John Hilton, Karen A. Gelmon, David W. Cescon, Anna V. Tinker, (unknown), Rachel Goodwin, Scott A. Laurie, Aaron R. Hansen, Samuel Aparício, John Soong, Linda Hagerman, (unknown), Philippe L. Bédard, Kathleen I. Pritchard, Dongsheng Tu, Lesley Seymour	7
8	A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. 2017 ·Breast Cancer Research and Treatment ·Vanessa Bernstein, Susan Ellard, Susan Dent, Dongsheng Tu, Mihaela Mates, Sukhbinder Dhesy‐Thind, Lawrence Panasci, Karen A. Gelmon, Mohammad Salim, (unknown), Mark Clemons, Doran Ksienski, Savita Verma, Christine Simmons, (unknown), K.N. Chi, Harriet Feilotter, Linda Hagerman, Lesley Seymour	79
9	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer 2017 ·Breast Cancer Research ·Stephen Chia, Susan Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen A. Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Rachel Goodwin, Tao Wang, Shingo Sakashita, Ming‐Sound Tsao, Elizabeth A. Eisenhauer, Penelope A. Bradbury	32
10	Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC) 2017 ·Cancer Research ·Vanessa Bernstein, Susan Ellard, Susan Dent, Karen A. Gelmon, Sukhbinder Dhesy‐Thind, Mihaela Mates, (unknown), Lawrence Panasci, Xinni Song, Mark Clemons, Dongsheng Tu, Linda Hagerman, Lesley Seymour	3
11	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187 2016 ·Investigational New Drugs ·Eric X. Chen, Derek J. Jonker, Lillian L. Siu, (unknown), Deborah S. Keller, (unknown), Linda Hagerman, Lesley Seymour	33
12	A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 2016 ·Journal of Thoracic Oncology ·Paul Wheatley‐Price, Quincy S. Chu, Maria Bonomi, Jean M. Seely, Ashish Gupta, Glenwood Goss, John Hilton, Ronald Feld, Christopher W. Lee, John R. Goffin, Andrew W. Maksymiuk, Nevin Murray, Linda Hagerman, Penelope A. Bradbury	29
13	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer 2016 ·Breast Cancer Research and Treatment ·Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy‐Thind, Susan Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, (unknown), Ming‐Sound Tsao, Alison L. Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth A. Eisenhauer, Penelope A. Bradbury	39
14	Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). 2013 ·Journal of Clinical Oncology ·Teresa M. Petrella, Catalin Mihalcioiu, Elaine McWhirter, Karl Bélanger, Kerry J. Savage, Xinni Song, Omid Hamid, Tina Cheng, M. L. Davis, Christopher W. Lee, Alan Spatz, Jose Gerard Monzon, Linda Hagerman, Bingshu E. Chen, Janet Dancey	13
15	A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. 2013 ·Journal of Clinical Oncology ·Stephen Chia, Susan Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen A. Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Elizabeth A. Eisenhauer, Penelope Ann Bradbury	1
16	Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study 2012 ·Journal of Clinical Oncology ·Teresa M. Petrella, Richard Tozer, Karl Bélanger, Kerry J. Savage, Ralph Wong, Michael Smylie, Suzanne Kamel‐Reid, Victor A. Tron, Bingshu E. Chen, Naomi Hunder, Linda Hagerman, Wendy Walsh, Elizabeth A. Eisenhauer	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact